89 completed, 12 recruiting, 11 terminated, 11 unknown. 138 Phase 3, 32 Phase 2.
Follow Opioid-Related Disorders: new trials by email Literature Review of Opioid-Related Disorders trials Research Report on Opioid-Related Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recovery Management Checkup Scalability and Sustainability Hybrid Experiment Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters), Recovery Management Checkups (RMC) delivered by staff under the research team (RMC by research staff) - Substance Use Disorder (SUD), Opioid Use Disorders | Phase 3 | Not yet recruiting | Chestnut Health Systems | 600 | 2026-11-02 | 2026-10-14 |
| Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT), Enhanced Treatment as Usual (ETAU) - Opioid Use Disorder, Chronic Pain | Phase 3 | Not yet recruiting | VA Office of Research and Development | 250 | 2026-11-02 | 2026-09-17 |
| Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol - Opioid Use Disorder | Phase 3 | Not yet recruiting | Montefiore Medical Center | 40 | 2026-10-01 | 2026-06-09 |
| Buprenorphine for Individuals in Jail extended-release buprenorphine (XR-B) - Opioid Use Disorder | Phase 3 | Recruiting | Friends Research Institute, Inc. | 240 | 2025-06-20 | 2026-06-04 |
| Adjunctive Cannabidiol for Recovery From Opioid Study Cannabidiol, Placebo - Opioid Use Disorder (OUD) | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 450 | 2025-06-13 | 2026-10-01 |
| Telemedicine XR-B for Individuals in Jail Extended Release Buprenorphine - Opioid Use Disorder | Phase 3 | Active not recruiting | Friends Research Institute, Inc. | 30 | 2025-06-01 | 2026-04-24 |
| Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits Mindfulness Oriented Recovery Enhancement, Patient-Centered Chronic Pain Management Visits - Chronic Pain, Prescription Opioid Misuse | Phase 3 | Recruiting | University of Utah | 300 | 2025-02-25 | 2026-02-03 |
| Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose Buprenorphine - Opioid Use Disorder | Phase 2 / Phase 3 | Recruiting | Rhode Island Hospital | 250 | 2025-01-06 | 2025-10-23 |
| Standard Versus High Dose ED-Initiated Buprenorphine Induction Buprenorphine - Opioid Use Disorder | Phase 3 | Recruiting | Yale University | 360 | 2024-12-06 | 2026-05-28 |
| CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial Tizanidine, MI-Opioid Taper, Placebo - Chronic Pain, Back Pain | Phase 3 | Recruiting | Stanford University | 375 | 2024-12-05 | 2026-05-06 |
| Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone - Opioid-Related Disorders, Substance-Related Disorders | Phase 3 | Completed | Yih-Ing Hser | 140 | 2024-10-14 | 2026-04-29 |
| Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Nalmefene Injection, Naloxone Injection - Opioid Overdose, Opiate Overdose | Phase 3 | Withdrawn | University of New Mexico | 2024-08-26 | 2025-02-10 | |
| Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial Olanzapine, Placebo - Misuse, Opioid | Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 69 | 2024-04-02 | 2026-09-10 |
| Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 Transcutaneous Cervical Vagal Nerve Stimulation, Sham Stimulation, [F-18]Fallypride - Withdrawal Symptoms, Opioid Use Disorder | Phase 3 | Recruiting | Emory University | 103 | 2024-02-20 | 2026-03-27 |
| Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl Naloxone Nasal Spray - Opioid Use Disorder | Phase 3 | Active not recruiting | University of Maryland, Baltimore | 3 | 2024-01-09 | 2026-07-27 |
| Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE) Buprenorphine Transdermal Matrix Patch, Sham patch - Opioid Use Disorder, Pregnancy Related | Phase 3 | Completed | Washington University School of Medicine | 7 | 2023-11-27 | 2026-09-10 |
| Mobile & Online-Based Interventions to Lessen Pain Empowered Relief On-Demand, Health Education - Chronic Pain, Opioid Misuse | Phase 3 | Completed | Stanford University | 234 | 2023-08-23 | 2025-12-18 |
| Treating Polysubstance Use Using a Novel Digital Technology DynamiCare Health, Methadone Treatment-As-Usual - Opioid Use, Opioid Use Disorder | Phase 3 | Active not recruiting | Friends Research Institute, Inc. | 240 | 2023-07-26 | 2026-05-19 |
| Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder Buprenorphine/naloxone, Placebo - Opioid-use Disorder | Phase 2 / Phase 3 | Recruiting | New York State Psychiatric Institute | 180 | 2023-04-18 | 2026-05-19 |
| High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED) High Dose Buprenorphine, Standard Buprenorphine Dose - Opioid Use Disorder | Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 140 | 2023-04-06 | 2026-07-30 |
Showing 20 of 138. Sign in to see all of them.
Heroin Dependence (19) · Substance-Related Disorders (17) · Chronic Pain (7) · Behavior, Addictive (5) · Substance Withdrawal Syndrome (5) · Cocaine-Related Disorders (4) · HIV Infections (4) · Alcoholism (3) · Amphetamine-Related Disorders (3) · Acquired Immunodeficiency Syndrome (2) · Agnosia (2) · Morphine Dependence (2) · Narcotic-Related Disorders (2) · Neonatal Abstinence Syndrome (2)
Chemically-Induced Disorders (137) · Mental Disorders (137) · Narcotic-Related Disorders (136) · Substance-Related Disorders (121) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (10) · Neurologic Manifestations (9) · Behavior (8) · Immune System Diseases (7) · Urogenital Diseases (7) · Blood-Borne Infections (6) · Communicable Diseases (6) · Genital Diseases (6) · Immunologic Deficiency Syndromes (6)
Buprenorphine (38) · Buprenorphine, Naloxone Drug Combination (30) · vivitrol (16) · Methadone (12) · Naltrexone (11) · Therapeutics (6) · Heroin (4) · Morphine (4) · lofexidine (4) · Naloxone (3) · Sublocade (3) · Cannabidiol (2) · Counseling (2) · Dronabinol (2) · Memantine (2)
New York State Psychiatric Institute (14) · Friends Research Institute, Inc. (8) · Titan Pharmaceuticals (7) · University of California, Los Angeles (7) · University of Pennsylvania (7) · Yale University (7) · Alkermes, Inc. (5) · Butler Hospital (5) · Johns Hopkins University (4) · University of British Columbia (4) · Indivior Inc. (3) · National Institute on Drug Abuse (NIDA) (3) · Universiti Sains Malaysia (3) · BioDelivery Sciences International (2) · Braeburn Pharmaceuticals (2)
United States (106) · Canada (6) · China (5) · Russia (4) · Malaysia (3) · Norway (3) · Australia (2) · Germany (2) · Taiwan (2) · Austria (1) · Denmark (1) · France (1) · Georgia (1) · Hungary (1) · India (1)
Walter Ling, M.D. (8) · Adam Bisaga, MD (3) · Frederick G Moeller, MD (2) · George E Woody, MD (2) · Katherine L. Beebe, Ph.D. (2) · Maria A. Sullivan, MD, PhD (2) · Michael D Stein, MD (2) · Michael L Dennis, PhD (2) · Michael S Gordon, DPA (2) · Richard Schottenfeld, M.D. (2) · Vicknasingam Kasinather, PhD (2) · Aaron D Fox, MD, MS (1) · Alexander Okhapkin, Prof. (1) · Alexander Sofronov, Prof. (1)
PMID 40342086, PMID 35287034, PMID 37657559, PMID 32002194, PMID 34752714, PMID 12873949, PMID 1517644, PMID 15919269, PMID 16102908, PMID 17341537, PMID 17628351, PMID 18612373, PMID 18855822, PMID 18984887, PMID 19149822, PMID 19159475, PMID 19339140, PMID 19692689, PMID 19721480, PMID 19948382, PMID 20155590, PMID 20393347, PMID 20403021, PMID 20598836, PMID 20626379, PMID 20707781, PMID 20940383, PMID 21142534, PMID 21489407, PMID 21491290, PMID 21529928, PMID 21653649, PMID 21715107, PMID 21791093, PMID 21852093, PMID 21854273, PMID 21924552, PMID 22013534, PMID 22024000, PMID 22065255, PMID 22088886, PMID 22215271, PMID 22227789, PMID 22276954, PMID 22281120, PMID 22864399, PMID 22882399, PMID 22945623, PMID 23021099, PMID 23036218
R18DA006082 (2), 1RC2DA028910-01 (1), 2025 (1), 4UH3DA048502 (1), 5UG1DA040316-05 (1), 5UH3DE028860-05 (1), I01RD000376 (1), K23DA020000 (1), K24DA053564 (1), R01DA006266 (1), R01DA009413 (1), R01DA010746 (1), R01DA011444 (1), R01DA014718 (1), R01DA015764 (1)